SCHEMBL2774258

SCHEMBL2774258

CCCCn1c(=O)[nH]c2sc(CC)cc2c1=O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.54
LMNA P02545 1/20 0.54
HTT P42858 1/20 0.54
QPCT Q16769 4/20 0.52
HPGD P15428 2/20 0.46
CYP2C9 P11712 2/20 0.46
POLB P06746 2/20 0.46
KDM4E B2RXH2 1/20 0.44
GAA P10253 1/20 0.44
HSD17B10 Q99714 1/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
PDE4A P27815 2/20 0.44
ADORA2A P29274 2/20 0.44
PDE4B Q07343 2/20 0.44
PDE4C Q08493 2/20 0.44
PDE4D Q08499 2/20 0.44
ADORA3 P0DMS8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2777323 0.84 POLB (0.52) ALDH1A1LMNAHTTQPCTHPGD
SCHEMBL2773547 0.83 ALDH1A1 (0.52) ALDH1A1LMNAHTTQPCTHPGD
SCHEMBL2775047 0.81 ADORA2B (0.54) ALDH1A1LMNAHTTQPCTHPGD
SCHEMBL2773068 0.80 ALDH1A1 (0.49) ALDH1A1LMNAHTTQPCTHPGD
SCHEMBL2776971 0.79 ALDH1A1 (0.48) ALDH1A1LMNAHTTQPCTHPGD
SCHEMBL2774219 0.79 ALDH1A1 (0.50) ALDH1A1LMNAHTTQPCTHPGD
SCHEMBL2775229 0.78 AGTR1 (0.51) ALDH1A1LMNAHTTQPCTHPGD
SCHEMBL2774914 0.78 ALDH1A1 (0.47) ALDH1A1LMNAHTTQPCTHPGD
SCHEMBL2772610 0.78 HPGD (0.56) ALDH1A1LMNAHTTQPCTHPGD
SCHEMBL2774317 0.77 HPGD (0.53) ALDH1A1LMNAHTTQPCTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8501750-B2 Heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-08-06 US disclosed
US-8501750-B2 Heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-08-06 US disclosed
US-8501750-B2 Heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-08-06 US disclosed
EP-2253630-A1 Heterocyclic compound and use thereof Takeda Pharmaceutical Company Limited (JP) 2010-11-24 EP disclosed
US-20100137281-A1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-06-03 US disclosed
US-20100137281-A1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-06-03 US disclosed
US-20100137281-A1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-06-03 US disclosed
EP-2151440-A1 HETEROCYCLIC COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-02-10 EP disclosed
EP-2151440-A1 HETEROCYCLIC COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-02-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137281-A1 HETEROCYCLIC COMPOUND AND USE THEREOF PCSK9, APOB, REN ALDH1A1 1296/4885LMNA 552/4885HTT 55/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.